Journal Image
Current Drug Delivery
ISSN (Print): 1567-2018
ISSN (Online): 1875-5704
Epub Full Text Article
DOI: 10.2174/1567201811666140609154949      Price:  $95

Paclitaxel Formulations: Challenges and Novel Delivery Options

Author(s): Chetan Nehate, Sharad Jain, Ankit Saneja, Vaibhav Khare, Noor Alam, Ravindra Dubey and Prem N Gupta
Paclitaxel (PTX), a taxane plant product, is one of the most effective broad-spectrum anti-cancer agents and approved for the treatment of a variety of cancers including ovarian, breast, lung, head and neck as well as Kaposi’s sarcoma. Poor aqueous solubility and serious side effects associated with commercial preparation of PTX (Taxol®) triggered the development of alternative PTX formulations. Over past three decades plethora of research work have been done in order to develop cremophor free formulations. Various nanocarriers systems including nanoparticles, liposomes, micelles, bioconjugates, dendrimers have been employed in order to improve its solubility and eliminate undesired side effects. These nanocarriers offers advantage of high degree of encapsulation and cellular uptake, escape from elimination by P-glycoprotein (P-gp) mediated efflux and can be explored for targeted drug delivery. The potential of these nanocarriers can be reflected by the fact that various nanocarriers of PTX are in different stages of clinical trials and a few have already been commercialized including Abraxane®, Lipusu and Genexol PM®. This review focuses on the various challenges associated with PTX formulation development, limitations of existing formulation and novel approaches for the development of alternative formulations for PTX and also highlights the development of novel formulations in clinical settings
Cancer, Drug delivery systems, Liposomes, Nanoparticles, Paclitaxel
Formulation & Drug Delivery Division CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-Tawi-180001, India